

2024 Antibigram (January-December)

<b>Gram Negative Organisms<sup>1</sup></b> Legend: <ul style="list-style-type: none"><li>Numbers represent % of isolates tested that were susceptible to antibiotic</li><li>(Total number of isolates)</li><li>↑ ≥ 5% increase in Susceptibility from Previous Year</li><li>↓ ≥ 5% decrease in Susceptibility from Previous Year</li></ul>		Ampicillin	Amp/sulbactam	Cefazolin <sup>2</sup> (uncomplicated UTI)	Cefazolin <sup>2,10</sup> (infections other than uncomplicated UTI)	Cefepime <sup>3</sup>	Ceftazidime	Ceftriaxone	Ciprofloxacin <sup>6</sup>	Gentamicin	Levofloxacin <sup>6</sup>	Meropenem	Pip/Tazobactam <sup>3</sup>	Trimethoprim/sulfamethoxazole	Nitrofurantoin Urinary Tract Infections only
<i>Escherichia coli</i> (1754)		60	67	93	68	99 <sup>10</sup>	97	95	86	94	85	100	95	84	97
<i>Enterobacter</i> species (122)		-	-	-	-	98	89	- <sup>5</sup>	92	100	93	- <sup>7</sup>	87	90	22↓
<i>Klebsiella</i> species (422)		0	82	88	78	96 <sup>10</sup>	92	89	86	98	88	100	94	89	34↓
<i>Proteus</i> species (166)		84↑	93	96	4	99 <sup>10</sup>	99	98	85	99	87	100	100	89	0
<i>Pseudomonas aeruginosa</i> (198)		-	-	-		94 <sup>4</sup>	96	-	87	-	79	91	96	-	-

<b>Gram Positive Organisms</b> Legend: • Numbers represent % of isolates tested that were susceptible to antibiotic • (Total number of isolates for that organism) ⬆ ≥ 5% increase in Susceptibility from Previous Year ⬇ ≥ 5% decrease in Susceptibility from Previous Year	Ampicillin	Ceftriaxone Non-meningitis	Ceftriaxone Meningitis	Ciprofloxacin <sup>10</sup>	Clindamycin	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Oxacillin <sup>8</sup>	Penicillin	Penicillin Non-meningitis	Penicillin Meningitis	Tetracycline	Trimethoprim/ sulfamethoxazole	Vancomycin	Nitrofurantoin Urinary Tract infections only
Methicillin Susceptible <i>Staphylococcus aureus</i> (403)	-	-	-	93	83	67	100	95	100	100	0	-	-	93	98	100	18/18 <sup>9</sup>
Methicillin Resistant <i>Staphylococcus aureus</i> (270)	-	-	-	57	80	13	100	57	100	0	0	-	-	87	84	100	20/20 <sup>9</sup>
<i>Staphylococcus</i> coagulase negative (210)	-	-	-	73	73⬆	59⬆	94	74	100	53⬆	0	-	-	83	80⬆	100	98
<i>Enterococcus faecalis</i> (198)	100	-	-	77	-	-	-	78	97	-	98	-	-	-	-	96	99
<i>Enterococcus faecium</i> <sup>10</sup> (48)	13	-	-	6	-	-	-	8	94	-	13	-	-	-	-	56	14
<i>Streptococcus pneumoniae</i> <sup>10</sup> (39)	-	100	92	-	77	61	-	100	100	-	-	100	72	74	-	100	-
<i>Streptococcus agalactiae</i> (Group B) <sup>9</sup> (15)	15/15	-	-	-	5/15	5/15	-	15/15	15/15	-	15/15	-	-	-	-	15/15	-

1. New susceptibility cards were implemented mid-2024 for Gram-negative organisms. Amikacin, cefoxitin, and tobramycin results have been removed as they are no longer tested at RPMC. Ertapenem results will be included starting with the 2025 antibiogram.
2. Cefazolin for uncomplicated UTIs: includes only results of urine cultures for *E. coli*, *K. pneumoniae*, and *P. mirabilis*. Cefazolin for infections other than uncomplicated UTIs (implemented mid-2024): includes results of all cultures for *E. coli*, *K. pneumoniae*, and *P. mirabilis*.
3. Susceptible Dose Dependent (SDD) results are not included in the % susceptible.
4. Cefepime tested by manual method on *Pseudomonas aeruginosa* prior to implementation of new breakpoints.
5. Ceftriaxone results for *Enterobacter* species are not provided due to testing limitations. Ceftriaxone is not suggested by IDSA for treatment of invasive infections caused by *Enterobacter cloacae* complex and *Enterobacter (Klebsiella) aerogenes*.
6. Ciprofloxacin and levofloxacin results for listed Gram-negative organisms are only provided for isolates tested after breakpoints were updated midyear to reflect new CLSI standards. Trend assessment not provided given change in number of isolates tested.
7. Meropenem results for *Enterobacter* species are not provided due to testing limitations. Of 122 *Enterobacter* isolates, 103 were identified as susceptible to meropenem. Susceptibility could not be determined for the remaining 19 isolates.
8. Oxacillin is tested as a surrogate for methicillin and nafcillin.
9. Reported as actual number of isolates susceptible. Trend assessment not provided due to small number of isolates.
10. Trend assessment not provided due to change in reporting format from previous year.